NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.

RecruitingNA

Sponsor: China-Japan Friendship Hospital

Conditions: Obesity

Interventions: BS-GLP1RA group, BS group

Countries: China

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. Given the lack of multi-regional validation in China's diverse population, this multicenter study aims to confirm the real-world effectiveness and generalizability of bariatric surgery plus GLP-1RA across distinct regional cohorts.

Eligibility overview

Sex: ALL

Age: 16 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).
2. obesity:BMI ≥27.5 kg/m².
3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
4. Age range: 16-70 years (inclusive).
5. Informed consent: Willing participation with documented consent.

Exclusion Criteria:

1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.
2. Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.
3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).
4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.
5. Significant comorbidities:

Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR \<30 mL/min/1.73m²) Active malignancy (except non-melanoma skin cancers) Autoimmune disorders requiring immunosuppression Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression)

Locations (7)

Xingtai, Hebei, China
Zhengzhou, Henan, China
Baotou, Inner Mongolia, China
Jinan, Shandong, China
Datong, Shanxi, China
Kunming, Yunnan, China
Beijing, China